Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Decoy TherapeuticsDCOY +4.85%23 Market Cap is $2.19 Mil as of Aug. 01, 2026. GuruFocus rates DCOY with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,422 Biotechnology companies, Decoy Therapeutics ranks worse than 95.22% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Decoy Therapeutics's share price for the quarter that ended in Mar. 2026 was $6.5306. Decoy Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 0.53 Mil. Therefore, Decoy Therapeutics's market cap for the quarter that ended in Mar. 2026 was $3.47 Mil.
Decoy Therapeutics's quarterly market cap
increased
from Sep. 2025 ($3.48 Mil) to Dec. 2025 ($4.14 Mil) but then
declined
from Dec. 2025 ($4.14 Mil) to Mar. 2026 ($3.47 Mil).
Decoy Therapeutics's annual market cap
declined
from Dec. 2023 ($2.81 Mil) to Dec. 2024 ($2.65 Mil) but then
increased
from Dec. 2024 ($2.65 Mil) to Dec. 2025 ($4.14 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Decoy Therapeutics's Enterprise Value for Today is $0.51 Mil.
Decoy Therapeutics (NAS:DCOY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Decoy Therapeutics Market Cap Related Terms
Decoy Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Decoy Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Decoy Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Decoy Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Decoy Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Decoy Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Decoy Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Decoy Therapeutics (DCOY) has a Market Cap of $2.19 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Decoy Therapeutics and its competitors. According to the industry distribution chart, Decoy Therapeutics ranks #1354 out of 1422 companies in the Biotechnology industry, placing it in the top 95.2%.
Is Decoy Therapeutics' Market Cap too high?
Decoy Therapeutics' current Market Cap is $2.19 Mil. The Biotechnology industry median Market Cap is 109.62. Decoy Therapeutics' value of $2.19 Mil is 98% below this industry median. Based on the distribution chart, Decoy Therapeutics ranks #1354 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' Market Cap compare to PKTX and CASIF?
According to the Biotechnology industry distribution chart, Decoy Therapeutics ranks #1354 out of 1422 companies for Market Cap. This places Decoy Therapeutics in the lower half of its industry. The industry median Market Cap is 109.62. Decoy Therapeutics' value of $2.19 Mil is 98% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 109.62, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Decoy Therapeutics's current Market Cap of $2.19 Mil is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Decoy Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 109.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Decoy Therapeutics's current Market Cap is $2.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (DCOY) has a current Market Cap of $2.19 Mil. The current Market Cap is $2.19 Mil and 98% below the Biotechnology industry median of 109.62. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Decoy Therapeutics (DCOY), the current Market Cap is $2.19 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score
Get the complete analysis for DCOY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DCOY has been successfully added to your 
